Emerging Therapeutics for Rare Neuromuscular Diseases: Pipeline Analysis
2022-12-01
上市批准免疫疗法
NEW YORK, Dec. 1, 2022 /PRNewswire/ --
Muscle weakness, cramps, and impaired musculoskeletal functions that occur due to rare defects in nerve and muscle cells characterize neuromuscular disorders (NMDs). The disorders are largely classified as motor neuron diseases, hereditary ataxias, peripheral nerve disorders, neuromuscular junction transmission disorders, and myopathies.
Read the full report: https://www.reportlinker.com/p06368651/?utm_source=PRN
NMDs present significant clinical challenges because of disease heterogeneity and rarity of occurrence.
The lack of measurable early disease markers and clinical outcomes further complicates the management of such disorders.Biologics presents a personalized and targeted method to treat NMDs and is a promising treatment class.
An overview of the global clinical trial landscape for emerging Phase 1, 2, and 3 treatments revealed that Amyotrophic LateralAmyotrophic Lateral Sclerosis (ALS), Myasthenia GravisMyasthenia Gravis (MG), Duchenne Muscular Dystrophy (DMD), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Diabetic Neuropathy (DN), and Spinal Muscular Atrophy (SMA) are the key hotspots for clinical studies.
These indications are likely to witness new drug developments.
Frost & Sullivan’s research, “Emerging Therapeutics for Rare Neuromuscular Diseases: A Pipeline Analysis†explores emerging biologics across these six NMDs.Key biologics emerging for these rare NMDs include stem cell therapies, other cell-based treatments, gene therapies, RNA therapeutics, immunotherapies, and other protein/peptide-based treatments.
There were 3 recent US FDA approvals for NMD RNA therapies: Nusinersen for SMA and Eteplirsen for DMD in 2016, and Golodirsen for DMD in 2019.Furthermore, Sarepta’s Casimersen for DMD and argenx’s efgartigimod for MG were approved as recently as 2021.
Biologics have opened doors for ground-breaking disease-modifying treatments and will transform the quality of life for patients across the world.While biologics may appear to cost more than small molecule treatments, they provide a personalized and, in some cases, the only treatment option.
They can also be less expensive than lifetime treatment costs for certain rare NMDs.
For example, Zolgensma’s $2.1 million price tag (approximate) is still lower than the standard medical costs incurred for SMA patients in a lifetime.
Furthermore, the evolving payer landscape is likely to get more standardized in the coming years to offer greater access to biologicals.
Therefore, biologics are suitably poised to transform the rare NMD landscape with personalized and targeted treatment strategies and will provide life-saving treatment options for fatal neuromuscular conditions.Key Points DiscussedWhat are the key emerging biologics for NMDs with high clinical activity?What are the key drivers or challenges for biologics development across NMDs?How do venture funding and patent landscapes look for NMD biologics?Who are the key industry participants developing biologics for NMDs?What are the clinical trends emerging across each biologic category for NMDs?Which biologic categories provide promising growth opportunities for NMD management?
Read the full report: https://www.reportlinker.com/p06368651/?utm_source=PRN
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
靶点
-药物
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。